Compare
Up to four compounds, side by side.
Useful for choosing between similar peptides or planning a stack.
Add a peptide
| Attribute | GLP-1 Agonist Dulaglutide |
|---|---|
| Summary | Weekly GLP-1 with cardiovascular outcome data in T2D. |
| Mechanism | Long-acting GLP-1 fusion protein — weekly dosing. |
| Top outcomes |
|
| Evidence | established |
| Half-life | ~5 days |
| Administration | subq |
| Legal status | rx only |
| Safety | Nausea on titration; well-tolerated long term. |